The Association of Micro-RNA 21 and Hypertension: A Meta-Analysis
By: Caihong Xin, Wei He, Xin Sun, Mianxian Li and Hongli Wang
References
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JJ, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206–1252. DOI: 10.1161/01.HYP.0000107251.49515.c2
- Janelle B, Kenyon R. Hypertension guidelines and interventions. Prim Care. 2024; 51(1): 41–52. DOI: 10.1016/j.pop.2023.07.002
- Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015; 386(9995): 801–812. DOI: 10.1016/S0140-6736(14)61468-9
- Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134(6): 441–450. DOI: 10.1161/CIRCULATIONAHA.115.018912
- Zaiou M. Circular RNAs in hypertension: Challenges and clinical promise. Hypertens Res. 2019; 42(11): 1653–1663. DOI: 10.1038/s41440-019-0294-7
- Sekar D, Shilpa BR, Das AJ. Relevance of microRNA 21 in different types of hypertension. Curr Hypertens Rep. 2017; 19(7):
57 . DOI: 10.1007/s11906-017-0752-z - Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: Novel targets in essential hypertension. J Hum Hypertens. 2014; 28(8): 510–516. DOI: 10.1038/jhh.2013.117
- Cengiz M, Yavuzer S, Kılıçkıran Avcı B, Yürüyen M, Yavuzer H, Dikici SA, et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015; 37(8): 643–649. DOI: 10.3109/10641963.2015.1036064
- Kara SP, Ozkan G, Yılmaz A, Bayrakçı N, Güzel S, Geyik E. MicroRNA 21 and microRNA 155 levels in resistant hypertension, and their relationships with aldosterone. Renal Failure. 2021; 43(1): 676–683. DOI: 10.1080/0886022X.2021.1915800
- Suzuki K, Yamada H, Fujii R, Munetsuna E, Yamazaki M, Ando Y, et al. Circulating microRNA-27a and –133a are negatively associated with incident hypertension: A five-year longitudinal population-based study. Biomarkers. 2022; 27(5): 496–502. DOI: 10.1080/1354750X.2022.2070281
- Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 5 Aug 2014). - Kontaraki JE, Marketou ME, Parthenakis FI, Maragkoudakis S, Zacharis EA, Petousis S, et al. Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. J Am Soc Hypertens. 2015; 9(10): 802–810. DOI: 10.1016/j.jash.2015.07.013
- Jiabing L, Wenli C, Jianming Z, Yuping W, Shaowei L, Huangyuan L, et al. Association between hypertension and serum microRNA21 and microRNA133a in ocean seamen. Chin J Ind HYG OCCUP DIS. 2016; 34(06): 412–415.
- Wang X, Tanwei X, Hua C, Juanfen L, Xiaoyu D, Tianran C, et al. Correlation between blood pressure response and blood microRNA expression during exercise test in patients with hypertension. Shanghai Med J. 2017; 40(06): 368–373.
- Ying W, Yuqing H, Cheng H, Jie L, Dan Z, Xueju Y, et al. The relationship and predictive value of plasma miR-21 with subclinical atherosclerosis in hypertension patients. South China Journal of Cardiology. 2017; 18(02): 127–135.
- Hijmans JG, Diehl KJ, Bammert TD, Kavlich PJ, Lincenberg GM, Greiner JJ, et al. Association between hypertension and circulating vascular-related microRNAs. J Hum Hypertens. 2018; 32(6): 440–447. DOI: 10.1038/s41371-018-0061-2
- Yildirim E, Ermis E, Allahverdiyev S, Ucar H, Yavuzer S, Cengiz M. Circulating miR-21 levels in hypertensive patients with asymptomatic organ damage. Medicine. 2019; 98(39):
e17297 . DOI: 10.1097/MD.0000000000017297 - Shuang W, Hongliang Z, Feng Z. Correlation of microRNA-21 with essential hypertension and left ventricular remodeling. Heilongjiang Medicine And Pharmacy. 2022; 45(01): 77–78.
- He X, Ma R, Li Y, Wang H, Yan Y, Mao Y, et al. Association of H-type hypertension with mir-21, mir-29, and mir-199 in Kazahks of Xinjiang, China. Int J Hypertens. 2022; 2022: 1–10. DOI: 10.1155/2022/4632087
- Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009; 37(4): 918–925. DOI: 10.1042/BST0370918
- Krichevsky AM, Gabriely G. miR-21: A small multi-faceted RNA. J Cell Mol Med. 2009; 13(1): 39–53. DOI: 10.1111/j.1582-4934.2008.00556.x
- Qin S, Zhang C. MicroRNAs in vascular disease. J Cardiovasc Pharmacol. 2011; 57(1): 8–12. DOI: 10.1097/FJC.0b013e318203759b
- Li X, Wei Y, Wang Z. microRNA-21 and hypertension. Hypertens Res. 2018; 41(9): 649–661. DOI: 10.1038/s41440-018-0071-z
- Canfran-Duque A, Rotllan N, Zhang X, Fernandez-Fuertes M, Ramirez-Hidalgo C, Araldi E, et al. Macrophage deficiency of miR-21 promotes apoptosis, plaque necrosis, and vascular inflammation during atherogenesis. Embo Mol Med. 2017; 9(9): 1244–1262. DOI: 10.15252/emmm.201607492
- Hinkel R, Ramanujam D, Kaczmarek V, Howe A, Klett K, Beck C, et al. Anti miR-21 prevents myocardial dysfunction in a pig model of ischemia/reperfusion injury. J Am Coll Cardiol. 2020; 75(15): 1788–1800. DOI: 10.1016/j.jacc.2020.02.041
- Zhang C. MicroRNAs: Role in cardiovascular biology and disease. Clin Sci (Lond). 2008; 114(12): 699–706. DOI: 10.1042/CS20070211
- Holland A, Enrick M, Diaz A, Yin L. Is miR-21 a therapeutic target in cardiovascular disease? Int J Drug Discov Pharm. 2023; 2(1): 26–36. DOI: 10.53941/ijddp.0201003
- Fernandes T, Magalhães FC, Roque FR, Phillips MI, Oliveira EM. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors. Hypertension. 2012; 59(2): 513–520. DOI: 10.1161/HYPERTENSIONAHA.111.185801
- Li H, Zhang X, Wang F, Zhou L, Yin Z, Fan J, et al. MicroRNA-21 lowers blood pressure in spontaneous hypertensive rats by upregulating mitochondrial translation. Circulation. 2016; 134(10): 734–751. DOI: 10.1161/CIRCULATIONAHA.116.023926
- Wang F, Fang Q, Chen C, Zhou L, Li H, Yin Z, et al. Recombinant adeno-associated virus-mediated delivery of MicroRNA-21–3p lowers hypertension. Molecular Therapy – Nucleic Acids. 2018; 11: 354–366. DOI: 10.1016/j.omtn.2017.11.007
- Jafari-Nozad AM, Rostami N, Esmaeili M, Vahdati H, Hosseini S, Farkhondeh T, et al. A review of the dual role of MicroRNA-21 in cardiovascular diseases: Risk factor or a potential therapeutic target. Curr Mol Pharmacol. 2024; 17:
e18761429287057 . DOI: 10.2174/0118761429287057240116040703
DOI: https://doi.org/10.5334/gh.1325 | Journal eISSN: 2211-8179
Language: English
Submitted on: Nov 29, 2023
Accepted on: Apr 16, 2024
Published on: May 1, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2024 Caihong Xin, Wei He, Xin Sun, Mianxian Li, Hongli Wang, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.